Abstract Human equilibrative nucleoside transporter 1 (hENT-1) is a membrane nucleoside transporter mediating the intracellular uptake of nucleosides and their analogues. hENT-1 was recently reported to have a predictive role in intrahepatic cholangiocarcinoma (iCC) patients receiving adjuvant gemcitabine-based chemotherapy, but its biological and clinical significance in iCC remains unsettled. This study investigated the role of hENT-1 in regulating tumour growth and predicting the survival of 40 resected iCC patients not receiving adjuvant treatments. hENT-1 expression was found to be significantly higher in iCC than in the matched non-tumoural liver. Patients harbouring hENT-1 localised on the tumour cell membrane had a worse overall survival than membrane hENT-1enegative patients (median 21.2 months vs 30.3 months, p Z 0.031), with an adjusted hazard ratio of 2.8 (95% confidence interval 1.01 e7.76). Moreover, membrane hENT-1epositive patients had a higher percentage of Ki67-positive cells in tumour tissue than membrane hENT-1-negative patients (median 23% vs 5%, p < 0.0001). Functional analyses in iCC cell lines revealed that hENT-1 silencing inhibited
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Introduction
Intrahepatic cholangiocarcinoma (iCC) is a malignancy arising from the epithelial cells of the intrahepatic bile ducts and represents the second most common primary liver cancer after hepatocellular carcinoma [1] . Currently, the prognosis for iCC is discouraging, with the majority of patients not eligible for surgical resection (the only chance of long-term survival) and a five-year overall survival (OS) of approximately 5%e10% [2] . Unfortunately, the prognosis remains disappointing after curative-intent surgery, with a five-year survival rate ranging from 20% to 40% [3] . Although some clinicopathological variables (including tumour differentiation, staging, lymph node metastasis, nerve invasion, tumour size, resection margins and tumour location) have been suggested as prognostic factors in iCC patients after surgical resection [4] , few data have been reported on putative prognostic tissue biomarkers in this setting of patients.
Human equilibrative nucleoside transporter 1 (hENT-1) is a membrane nucleoside transporter expressed in most human cells [5] . Besides mediating the intracellular uptake of nucleoside analogue drugs, hENT-1 regulates the physiological cellular uptake of purine and pyrimidine nucleosides, the precursors of nucleotide triphosphates (NTPs) that are essential for DNA and RNA synthesis [5] . We recently reported that proper hENT-1 localisation on the tumour cell membrane is associated with a longer disease-free survival in cholangiocarcinoma (CC) patients who have undergone more than four cycles of adjuvant gemcitabine-based chemotherapy [6] .
The present study aimed to investigate the hypothesis that aberrant localisation of hENT-1 in tumour cells may also affect iCC tumour growth and patients' survival, due to impaired nucleoside uptake within tumour cells.
Materials and methods
Patients
Ninety-eight consecutive iCC patients underwent surgery with curative intent at S. Orsola-Malpighi University Hospital (Bologna, Italy) between January 2002 and December 2009. After radical resection (R0 or R1), patients meeting the following criteria were considered suitable for gemcitabine adjuvant chemotherapy: age !18 years, Eastern Cooperative Oncology Group Performance Status Scale (ECOG PS) 2, adequate white blood cell count, neutrophil count, platelet count, serum creatinine concentration and normal liver function values. Patients older than 77 years, with low ECOG PS (>2), impaired left ventricular ejection fraction or abnormal respiratory patterns or patients with white blood cell count <3500/Ml, platelet count <100,000/mL, renal dysfunction (creatinine concentration !1.5Â normal) or hepatic dysfunction (bilirubin and aspartate aminotransferase levels more than twice the upper normal value) were considered unfit for adjuvant treatment [6, 7] . Given the absence of any conclusive data on the efficacy of adjuvant chemotherapy after resection in CC, the decision on postoperative chemotherapy was left to the patient. Only iCC patients who did not receive adjuvant gemcitabine because they declined treatment were considered eligible for the present study, even if they met the criteria listed above. After surgery, patients were enrolled in a predefined follow-up program with visits every four months for the first two years and every six months thereafter. For patients who died, the survival time after surgery and cause of death were recorded.
Morphological classification of the tumours was based on the World Health Organisation criteria [8] . Tumours were graded as per the international tumournode-metastasis system [9] . The study was carried out in accordance with the ethical guidelines of the 1975 Declaration of Helsinki (and subsequent modifications).
Tissue microarray and immunohistochemistry
Tissue microarray (TMA) was constructed from formalin-fixed, paraffin-embedded tissue samples from each iCC patient. To account for intratumor heterogeneity in this malignancy [10] , three representative neoplastic cores for each case and two cores from the matched non-tumoural liver were assembled in the TMA block. Immunohistochemistry (IHC) for hENT-1 and Ki67 was performed on serial 3-mm-thick sections with antiehENT-1 (GeneTex, Inc. San Antonio, TX, USA) and anti-Ki67 (clone 30-9; Ventana Medical Systems, Tucson, AZ, USA) antibodies, respectively. IHC for hENT-1 was carried out with the Novolink Polymer Detection System (Leica Microsystems, Germany) as previously reported [6] .
A tumour was considered positive for membrane hENT-1 localisation when at least two out of three TMA iCC cores showed membrane positivity. For Ki67 evaluation, IHC was automatically performed using a Benchmark Ultra immunostainer (Ventana/Roche) in accordance with the following protocol: (a) dewaxing; (b) antigen retrieval in cell conditioning 1 for 36 min at 95 C; (c) incubation with primary antibody for 32 min at 37 C and (d) development using the UltraView Alkaline Phosphatase Red detection kit and counterstaining in haematoxylin II. Ki67 was considered overexpressed when !10% stained nuclei were observed in each TMA core. For each patient, the overall Ki67 labelling index was obtained from the mean value of three TMA cores. IHC was evaluated by three dedicated pathologists blinded to each other and to clinical data and patient outcomes.
Cell lines
The human iCC cell lines SNU-1079 and HUH-28 were obtained from the Korean Cell Line Bank (Seoul, Korea). Cell lines were cultured in Roswell Park Memorial Institute's medium (Euroclone, Milan, Italy), supplemented with 10% (v/v) heat-inactivated foetal bovine serum (Euroclone), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (SigmaeAldrich, St. Louis, MO, USA). Cells were grown at 37 C in a humidified atmosphere of 95% air and 5% CO 2 and routinely passaged using 0.025% trypsineethylene diamine tetra-acetic acid (Euroclone).
hENT-1 siRNA transfection
For hENT-1 siRNA transfection, SNU-1079 (2 Â 10 5 ) and HUH-28 (1 Â 10 4 ) cells were seeded in a six-well plate in antibiotic-free medium. Transfection was performed with Lipofectamine (Invitrogen) in Opti-minimum essential medium (MEM) medium (Invitrogen) following the manufacturer's instructions. hENT-1 silencing was carried out by TriFECTa RNAi Kit (IDT, Coralville, USA) following the manufacturer's protocol. A scramble siRNA was used on each experiment as a negative control. RNA and proteins were extracted 48 and 72 h after siRNA transfection.
RNA isolation and quantitative reverse-transcriptase polymerase chain reaction
Total RNA was isolated from tissue samples and cell lines using the AllPrep DNA/RNA Mini Kit (Qiagen, Valencia, CA) as per the manufacturer's instructions. A total of 0.5 mg of RNA was reverse-transcribed using ImProm-II Reverse Transcriptase (Promega Corporation, Madison, USA) following the manufacturer's protocol. hENT-1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA levels were analysed by quantitative reverse-transcriptase polymerase chain reaction using TaqMan Gene Expression Assays (Applied Biosystems, Carlsbad, CA, USA). Gene expression was expressed as DCt (Ct of the gene of interest normalised to Ct of GADPH). Fold change in mRNA expression was calculated based on the 2 ÀDDCt method.
Immunocytochemistry
HuH-28 and SNU-1079 cells were seeded (2.5 Â 10 4 cells/well) on a slide in a six-well plate and left to grow for 24 h. After a wash with PBS, cells were fixed with 4% paraformaldehyde for 5 min at room temperature. Cells were then washed with PBS, permeabilized with 0.5% Triton X-100 for 4 min, washed with PBS, incubated with PBS-BSA 3% for 30 min and subsequently with primary anti-hENT1 antibody (GeneTex, Inc. San Antonio, TX, USA), diluted 1:100 at 4 C overnight. Following primary antibody incubation, cells were washed with phosphate-buffered solution (PBS) and incubated with secondary antibodies for 1 h at room temperature. Cells were then washed with PBS, distilled H 2 O and finally developed in 3,3
0 -diaminobenzidine and counterstained with haematoxylin.
Nuclear morphological changes
Changes in nuclear morphology of SNU-1079 and HuH-28 cells transfected with hENT-1 siRNA were detected by the DNA-binding fluorochrome bis-benzimide stain (Hoechst 33,342; Sigma Chemical Co.). Briefly, SNU-1079 (2 Â 10 5 ) and Huh-28 (1 Â 10 4 ) cells were seeded in a six-well plate on a cover glass and transfected with hENT-1 siRNA as above described. At the end of incubation, 1 mg/ml Hoechst was added to each well for 30 min at 37 C in the dark. Cells were finally washed twice with PBS and photographed under a fluorescence microscope (Nikon Eclipse; Florence, Italy).
Western blot analysis
Proteins were extracted from tumour tissues and matched normal livers with radioimmunoprecipitation assay (RIPA) Lysis and Extraction Buffer (G-Biosciences, St. Louis, MO, USA) supplemented with cOmplete Mini protease inhibitors (Roche, Mannheim, Germany) and phosphatase inhibitors (Roche). In Huh-28 and SNU-1079 cell lines, cytosolic and membrane protein fractions were extracted using the Compartmental Protein Extraction Kit (Millipore), as per the manufacturer's instructions. Equal amounts of protein extracts were then separated in 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and gels and transferred to polyvinylidene difluoride membranes by standard methods. Membranes were immunoblotted with the following primary antibodies: antieequilibrative nucleoside transporter (ENT-1) (Abcam), antiecaspase-3 (Cayman Chemical Company, Ann Arbor, MI, USA), antiepoly-(ADP-ribose)polymerase-1 (PARP-1) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and antiebactin (Cell Signalling, Danvers, MA, USA). Digital images of X-ray films were quantified by ChemiDoc XRSþ (Image Lab Software, Bio-Rad).
Cell viability assays
Methyltetrazolium (MTT) and crystal violet colorimetric assays were used to assess cell viability. For each type of experiment, HuH-28 and SNU-1079 cells (1 Â 10 4 cells/ well) were plated in a 24-well plate in triplicate and allowed to adhere for 24 h. Cells were then transfected with hENT-1 siRNA as above described; after transfection, they were grown for 24, 48 and 72 h. At the end of incubation, cells were processed as follows: (a) MTT was added to each well, and cells were incubated at 37 C for 4 h. Formazan crystals were then dissolved in dimethyl sulfoxide (DMSO) and absorbance measured at 570 nm in a spectrophotometer (Thermofisher, USA); (b) cells were washed with PBS, fixed in 4% formaldehyde and stained with 1% crystal violet. Cells were washed twice with distilled H 2 O and dried completely. Crystal violet was solubilised with 10% acetic acid for 15 min and absorbance was measured at 570 nm in a spectrophotometer (Thermofisher, USA).
Cell cycle analysis
Cell cycle analysis was performed by flow cytometry. For this purpose, Huh-28 and SNU-1079 cells were seeded in 25 cm 2 flasks at a density of 4 Â 10 5 and transiently transfected with hENT-1 siRNA as previously described. After 72 h, cells were harvested by trypsinization, washed with PBS and incubated at 4 C for 16 h in the DNA-staining solution (0.1% Triton X-100, 0.1% sodium citrate and 50 mg/ml propidium iodide). DNA content was finally analysed using the FACSAria cell sorter (Becton Dickinson, Franklin Lakes, NJ, USA).
Statistical analysis
Summary statistics of continuous variables were expressed as median (range) and compared using ManneWhitney U test. Categorical variables were reported as numbers (percentages) and compared with Pearson's chi-squared test or Fisher's exact test, as appropriate. The main outcome measure was OS defined as the time from the date of iCC surgery to the date of death or the last follow-up. Data cut-off for OS analysis was December 31, 2016. Patients' survival curves were plotted using the KaplaneMeier method, and differences between groups were compared by log-rank test.
The association between hENT-1 localisation in tumour cells and OS was characterised by hazard ratios (HRs) along with their 95% confidence intervals (CIs). The limited number of patients did not allow the inclusion of all covariates in multivariable Cox proportional hazards regression models. Due to problems of sparse data, we did not retain the full model (i.e., adjusted for all potential confounders), but we ran a reduced model using the backwards procedure where the selection of the covariates was based on the relative change-in-estimate approach [11] . In addition to the forced variables (i.e., age and gender), we finally included disease stage, histological grade and tumour size at surgery. Age was included as a categorical variable based on tertiles, whereas tumour size was entered in the model as a binary variable on the basis of the Table 1 Baseline characteristics of the 40 iCC patients included in the study based on membrane hENT-1 localisation. median value. Tests based on the Schoenfeld residuals along with graphical methods were used to detect violations of the proportional hazard assumption [12] . To evaluate the predictive power of a model, Harrell's C index and corresponding 95% CI were calculated (using the package for STATA 14.2) [13, 14] .
To minimise the effect of potential confounders on selection bias, a propensity score was derived reflecting the probability of a patient expressing membrane hENT-1, given a set of possible confounders [15, 16] . To accomplish this, we first constructed a multivariable logistic regression model using hENT-1 localisation in tumour cells as a dependent variable and entering patient's covariates in the model. These variables included age (categorised by tertiles), gender, disease stage, histological grade and tumour size at surgery (entered as binary). Then, we fitted Cox proportional hazards regression models adjusted by propensity score included either as linear term or stratified on quintiles. For in vitro assays, differences between groups were analysed using Student t test. Cohen's k was used for interobserver agreement in the hENT-1 IHC evaluation. Statistical analyses were performed using Stata 14.2 SE (Stata Corporation, College Station, TX, USA). All the tests were two-sided, and a p value < 0.05 was defined as statistically significant.
Results
Patient characteristics
Of the 48 consecutive iCC patients considered fit for adjuvant gemcitabine but who did not receive treatment because they declined, eight were excluded from the study due to the lack of follow-up. Finally, 40 iCC patients were retrospectively included in the study; the main clinical-pathological variables are summarised in Table 1 . The cohort consisted of 19 men and 21 women with a median age at diagnosis of 63.5 years (range, 34e77). Median tumour size was 6 cm (range 2e18 cm). Tumours were grade I in 0 (0%) cases, grade II in 20 (50%) cases and grade III in 20 (50) cases. Five patients (12.5%) were classified as T1, 24 (60%) as T2 and 11 (27.5%) as T3. All iCCs were mass-forming type with associated areas of periductal infiltrating growth in two (5.0%) cases. Microvascular and/or perineural neoplastic invasion was present in 31 (77.5%) cases. Thirty-three (82.5%) iCCs arose on non-cirrhotic livers, two (5.0%) in livers with fibrous septa and five (12.5%) in cirrhotic livers. Twelve (30.0%%) patients had locoregional lymph node metastasis.
hENT-1 protein is expressed in iCC but not in matched non-tumoural liver tissues
Few data have been reported on hENT-1 expression in iCC and matched non-tumoural liver tissue. To better clarify this issue, we first evaluated hENT-1 mRNA expression in the tumour and matched non-tumoural liver counterpart from the 40 iCC patients included in the study. We observed that hENT-1 mRNA expression was significantly higher in tumours than in matched non-tumoural liver tissues (Fig. 1A) . To further validate these findings, hENT-1 protein level was determined by Western blot analysis. Twenty-eight (70%) of the 40 iCCs were found to express hENT-1 protein, whereas 12 (30%) tumour samples were negative (Fig. 1B) . Notably, all matched non-tumoural livers were negative for hENT-1 protein expression (Fig. 1B) . These findings were in line with IHC results (Fig. 2) . Indeed, IHC analysis of the matched non-tumoural liver revealed that hENT-1 was not expressed by either normal cholangiocytes or hepatocytes (Fig. 2aec). 
Membrane hENT-1 is associated with higher Ki67 proliferation index in iCC tissues
In the light of the physiological role of hENT-1 as a membrane transporter of nucleosides for NTP synthesis, we next investigated the possible association between hENT-1 cellular localisation and the proliferation marker Ki67. The interobserver agreement among the three pathologists in hENT-1 evaluation was good (k Z 0.83); the discordant cases were collegially discussed. IHC on TMA revealed that 12 (30%) cases were completely negative for hENT-1 expression in tumour tissue, 15 (37.5%) displayed only a cytoplasmic staining, whereas 13 (32.5%) showed a concomitant cytoplasmic/ membrane hENT-1 positivity (Fig. 3A) .
Eighteen (45%) of 40 cases showed a Ki67 nuclear staining !10%, whereas in 22 of 40 cases (55%), it was <10% (Fig. 3A) . Membrane hENT-1epositive patients were found to have a higher percentage of Ki67-positive cells in tumour tissue (median 23%, range 13e63%) than membrane hENT-1enegative patients (median 5%, range 0e15%) (p < 0.0001) (Fig. 3B) . In particular, only five membrane hENT-1enegative patients (18%) had Ki67-positive cells ! 10%, whereas all 13 membrane hENT-1epositive patients (100%) had Ki67-positive cells ! 10% (p < 0.0001) ( Table 2 ). In addition, survival analysis revealed that membrane hENT-1epositive patients had a shorter OS (median 21.2 months, range 3.5e52.5) than membrane hENT-1enegative patients (median 30.3 months, range 5.6e67) (Fig. 3C) . Estimates for the association between membrane hENT-1 localisation and OS are reported in Table 3 . Unadjusted estimates were close to those produced with the multivariable Cox regression analysis. The multivariable model had good discrimination (Harrel's C index 0.71, 95%CI 0.58e0.84). The estimates adjusted via propensity score were consistent with those obtained by the multivariable model alone. Membrane-positive hENT-1 was associated with shorter OS (adjusted HR by propensity score (linear term) 2.61, 95% CI 1.00e6.82; adjusted HR by propensity score (quintiles) 2.87, 95% CI 1.03e7.98) than membrane-negative hENT-1.
To further confirm the positive association between membrane hENT-1 and high Ki67 score, IHC analysis was performed in the independent cohort of 44 iCC patients belonging to our previous study [6] . Of these, 25 (57%) of the 44 cases showed a Ki67 nuclear staining !10%, whereas 19 (43%) had <10% ( Supplementary  Fig. 1A ). Membrane hENT-1epositive patients resulted in a higher percentage of Ki67-positive cells in tumour tissue (median 17.5%, range 9e45%) than membrane hENT-1enegative patients (median 8%, range 5e30%) (p < 0.0001) (Supplementary Fig. 1B) . Notably, in the subgroup of membrane hENT-1enegative patients, 10 (35.7%) of 28 cases had Ki67-positive cells ! 10%, whereas among membrane hENT-1epositive patients, 15 (93.7%) of 16 cases had Ki67-positive cells ! 10% (p Z 0.0002) (Supplementary Table 1) .
Overall, these findings strongly support the notion that membrane hENT-1 characterises iCCs with a high proliferation rate.
Membrane hENT-1 regulates cell growth and survival in iCC cell lines
To better clarify the involvement of membrane hENT-1 localisation in regulating iCC tumour growth, we evaluated the expression/localisation of the transporter in two iCC cell lines, HuH-28 and SNU-1079. Immunocytochemistry and Western blot analysis of both cytosolic and membrane fractions revealed that SNU-1079 cells expressed hENT-1 only in the cytoplasm, whereas HuH-28 cells expressed the transporter both in the cytoplasm and on the cell membrane ( Fig. 4A and  B) . Next, cell lines were transfected with hENT-1 siRNA. We observed a significant decrease in mRNA and protein expression in HuH-28 and SNU-1079 cells after 72 and 48 h of incubation, respectively (Fig. 4C) . Notably, hENT-1 silencing was associated with a significant decrease of HuH-28 cell growth at 72 h compared with scramble cells. Conversely, no significant change in cell growth was observed in SNU-1079 cells either at 48 or 72 h of hENT-1 silencing (Fig. 5A and B and Supplementary Fig. 2A and B) . Cell cycle analysis showed that hENT-1 silencing in HuH-28 cells resulted in an accumulation in G0-G1 and sub-G0 phase, with a corresponding decrease of G2/M and S phase fractions, compared with scramble cells (Fig. 5C) . Conversely, no significant differences in cell cycle phases were found between hENT-1 silenced and scramble SNU-1079 cells (Fig. 5D) . Further western blot analysis revealed that the increase in sub-G0 phase in HuH-28 silenced cells was related to apoptosis induction, as shown by caspase-3/PARP-1 cleavage in this cell line, but not in SNU-1079 cells (Fig. 5E and F, upper panel) . These results were in line with Hoechst staining that revealed the presence of typical apoptotic figures only in HuH-28 silenced cells (Fig. 5E and F, lower panel) .
Overall these findings suggest that membrane hENT-1 localisation is involved in the regulation of iCC cell growth and survival.
Discussion
Most iCCs are characterised by an aggressive biological behaviour and show rapid tumour growth; however the molecular mechanisms underlying this phenomenon have yet to be fully elucidated. The present study explored the possible involvement of the nucleoside transporter hENT-1 in regulating iCC tumour growth and predicting the survival of resected iCC patients not receiving adjuvant treatments. We observed that hENT-1 mRNA was expressed both in iCC and matched non-tumoural liver tissues, even if at lower levels. Conversely, hENT-1 protein was expressed only in iCC samples, suggesting a posttranscriptional regulation in non-tumoural liver. These findings are in line with previous studies reporting a higher expression of hENT-1 in proliferating cells than non-cycling growtharrested cells [17] . Indeed, in normal conditions the liver is a silent organ, with a very slow turnover of both hepatocytes and cholangiocytes. Conversely, iCC is characterised by a high cell turnover and proliferation activity, a condition requiring a considerable amount of nucleosides for NTP synthesis (essential to sustain DNA replication and RNA production during cell division) and that may justify the increased expression of hENT-1 in this tissue type. However, because an efficient intracellular uptake of nucleosides requires hENT-1 to be localised on the cell membrane [18, 19] , here, we hypothesised that an aberrant localisation of this transporter in tumour cells may result in impaired nucleoside uptake, thereby affecting the intracellular NTP pool and finally iCC tumour growth. In line with this hypothesis, a positive correlation between membrane hENT-1 and a high Ki67 score was found in our iCC cases. Conversely, iCCs expressing the transporter only in the cytoplasm were associated with a low Ki67 staining, similar to that observed in iCCs negative for hENT-1 expression. Notably, these findings were also confirmed in the independent cohort of 44 iCC patients belonging to our previous study [6] . Moreover, patients harbouring membrane hENT-1 in iCC tissue were found to have a shorter OS than membrane hENT1enegative patients, suggesting that hENT-1 tumour localisation could serve as a potential prognostic factor in this malignancy. Table 2 Correlation between hENT-1 membrane localisation and Ki67 labelling index in the 40 iCC patients included in the study. A high hENT-1 protein expression has been already reported to associate with shorter OS and high Ki67 score in ampullary carcinoma [20] . Even if the association between Ki67 staining and hENT-1 localisation has not been investigated in this previous study, it is conceivable that, similarly to our iCC cases (where membrane hENT-1 positivity invariably occurred together with a cytoplasmic positivity), some of the ampullary carcinomas with high hENT-1 cytoplasmic staining also had a concomitant membrane hENT-1 staining, not detectable because of important variables in IHC analysis (such as time of tissue fixation, type of fixation, long-term stability of the epitope and the specificity of the antibody used).
To better clarify the role of hENT-1 localisation in the regulation of iCC cell growth, functional analyses in iCC cell lines were performed. Previous studies have reported that an insufficient NTP supply within cells may result in dysfunctional proliferation, DNA damage and finally apoptosis [21] . Moreover, reduced expression of the isoform hENT-2 has been shown to result in a dramatic decrease in cell proliferation and dysregulation of the cell cycle, due to a lower incorporation of NTPs into DNA [22] . In line with these observations, hENT-1 silencing was found to inhibit cell proliferation and induce apoptosis in HUH-28 cells, expressing hENT-1 on the cell membrane. Conversely, no significant changes in these parameters were observed in silenced SNU-1079 cells expressing hENT-1 only in the cytoplasm. This last result is not totally surprising; indeed, although the uptake of nucleosides mostly occurs via hENT-1, other transporters (including hENT-2) may be involved in this process, even if to a lesser extent [22] . Therefore, failure of apoptosis induction in hENT1esilenced SNU-1079 cells could be related to the maintenance of a proper intracellular NTP pool by nucleoside transporters other than hENT-1.
In conclusion, the present study suggests that membrane hENT-1 characterises iCCs with a high proliferation rate and is associated with worse OS in resected patients not receiving adjuvant treatments. In the light of our previous study in the adjuvant setting [6] , overall, our findings support the notion that, similarly to human epidermal growth factor receptor 2 (HER2)/neu in breast cancer (where its overexpression associates with worse survival, but with response to anti-HER2 therapies [23] ), membrane hENT-1 may represent a worse prognostic factor, but a predictive factor of efficacy of gemcitabine-based chemotherapy, in iCC.
However, due to the retrospective nature of the present study and the limited number of included cases, further prospective studies on larger cohorts of iCC patients are required to confirm these results.
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